Compare LFVN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | RLYB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 89.2M |
| IPO Year | 1996 | 2021 |
| Metric | LFVN | RLYB |
|---|---|---|
| Price | $6.24 | $16.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 46.4K | 7.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.40 | ★ 6.16 |
| Revenue | ★ $203,204,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.73 | ★ $2.70 |
| Revenue Growth | 1.86 | ★ 43.00 |
| 52 Week Low | $3.90 | $0.48 |
| 52 Week High | $11.71 | $17.57 |
| Indicator | LFVN | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 46.15 |
| Support Level | $6.12 | $16.49 |
| Resistance Level | $6.78 | $17.30 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 33.77 | 22.78 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.